Skip to content

Safety and Effectiveness Assessment of Endovascular Recanalization for Nonacute Anterior Circulation Large Artery Occlusion

Safety and Effectiveness Assessment of Endovascular Recanalization for Nonacute Anterior Circulation Large Artery Occlusion

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055664
Enrollment
Unknown
Registered
2022-01-16
Start date
2022-01-17
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Stroke

Interventions

Group 1 :Drug treatment
Group 2:Endovascular treatment

Sponsors

Nanjing Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age: 40-75 years old; 2. DSA or CTA confirmed unilateral occlusion of the intracranial segment of the internal carotid artery or the middle cerebral artery, and the occlusion segment is within 2 cm; 3. The clinical symptoms and signs are consistent with the responsible vessel; 4. CTP/MRP showed hypoperfusion in the supply area of the responsible artery; 5. Occlusion in the non-acute stage, with onset time of more than 24 hours; 6. mRS score <= 1 before onset; 7. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with massive cerebral infarction and cerebral hemorrhage in the past; 2. Combined with intracranial aneurysm, intracranial arteriovenous malformation and other cerebrovascular malformations; 3. Internal carotid artery occlusion caused by Takayasu arteritis or dysplasia; 4. Patients who have been diagnosed with vascular dementia; 5. Allergy to aspirin or clopidogrel or corresponding contraindications; 6. Allergy to iodine agent or contrast agent, serum creatinine > 3 g/L or other contraindications for cerebral angiography; 7. mRS score > 1 before onset; 8. Other planned surgical operations or interventional treatments may require termination of the trial drug. Diagnosed or probable acute coronary syndrome; 9. Undergoing experimental drug or instrument test. Are undergoing experimental drug or device testing; 10. Women of childbearing age, pregnant or lactating women who have a negative pregnancy test but refuse to take effective contraceptive measures; 11. Participated in other clinical drug research in the past 30 days; 12. Patients with coronary heart disease or previous myocardial infarction before enrollment.

Design outcomes

Primary

MeasureTime frame
recurrence of stroke;

Countries

China

Contacts

Public ContactLi Jingwei

Department of Neurology, Drum Tower Hospital

ljw323@yeah.net+86 13675158558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026